Changes

{{Under Construction}}

{{Under Construction}}

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Acute Myeloid Leukemia (AML) with Minimal Differentiation]].

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-04. The original page can be found at [[HAEM4:Acute Myeloid Leukemia (AML) with Minimal Differentiation]].

}}</blockquote>

}}</blockquote>

==Primary Author(s)*==

==Primary Author(s)*==

==Definition / Description of Disease==

==Definition / Description of Disease==

This is a distinct entity in the World Health Organization (WHO) classification system within the section of [[Acute Myeloid Leukemia (AML), Not Otherwise Specified]]<ref name=":0">Arber DA, et al., (2017). Acute myeloid leukaemia,NOS in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J Editors. IARC Press: Lyon, France, p156-158.</ref>.  This entity does ''not'' meet the criteria for inclusion in any of the other AML groups (i.e. AML with Recurrent Genetic Abnormalities, AML with Myelodysplasia-Related Changes, or Therapy-Related Myeloid Neoplasms).

This is a distinct entity in the World Health Organization (WHO) classification system within the section of [[HAEM4:Acute Myeloid Leukemia (AML), Not Otherwise Specified]]<ref name=":0">Arber DA, et al., (2017). Acute myeloid leukaemia,NOS in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J Editors. IARC Press: Lyon, France, p156-158.</ref>.  This entity does ''not'' meet the criteria for inclusion in any of the other AML groups (i.e. AML with Recurrent Genetic Abnormalities, AML with Myelodysplasia-Related Changes, or Therapy-Related Myeloid Neoplasms).

• Recognized as a distinct entity in 1987<ref>{{Cite journal|last=Lee|first=M. S.|last2=Chang|first2=K. S.|last3=Trujillo|first3=J. M.|last4=McCredie|first4=K. B.|last5=Keating|first5=M. J.|last6=Freireich|first6=E. J.|last7=Stass|first7=S. A.|date=1987|title=T-cell receptor gamma chain gene rearrangement in acute myelogenous leukemia--evidence for lymphoid lineage prematurity|url=https://www.ncbi.nlm.nih.gov/pubmed/2848796|journal=Hematologic Pathology|volume=1|issue=2|pages=93–98|issn=0886-0238|pmid=2848796}}</ref>

• Recognized as a distinct entity in 1987<ref>{{Cite journal|last=Lee|first=M. S.|last2=Chang|first2=K. S.|last3=Trujillo|first3=J. M.|last4=McCredie|first4=K. B.|last5=Keating|first5=M. J.|last6=Freireich|first6=E. J.|last7=Stass|first7=S. A.|date=1987|title=T-cell receptor gamma chain gene rearrangement in acute myelogenous leukemia--evidence for lymphoid lineage prematurity|url=https://www.ncbi.nlm.nih.gov/pubmed/2848796|journal=Hematologic Pathology|volume=1|issue=2|pages=93–98|issn=0886-0238|pmid=2848796}}</ref>